Blood cancer drug safety tracked over 5 years

NCT ID NCT07162181

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment every 12 weeks for about 5 years. The main goal is to track serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell neoplasm lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL LYMPHOMA LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL LYMPHOMA, NON-HODGKIN

Contacts and locations

Show contact details

Locations

Beijing Cancer hospital

Beijing, 100142, China
Blood Institute of the Chinese Academy of Medical science

Tianjin, 300020, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Shanghai East Hospital

Shanghai, 200123, China
Sun Yat-sen University Cancer Center

Guangzhou, 510060, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, 430022, China